16th week of 2013 patent applcation highlights part 43 |
Patent application number | Title | Published |
20130096046 | SOAP STRUCTURE - A soap structure includes a core portion having dimensions defined according to general users' palm size for a user to conveniently grip it; and at least one layer of soap portion being covered over the core portion, so that the core portion is completely enclosed in the soap portion. With the core portion being sized suitable for gripping and covered by one or more layers of soap portion, the soap structure can be conveniently gripped even if the layers of soap portion gradually reduce in mass and size after being used many times. | 2013-04-18 |
20130096047 | Surfactant Component And A Composition Including The Same - A surfactant component and a composition comprising the same are provided. The surfactant component comprises a first surfactant, a second surfactant, and water. The first surfactant comprises an alcohol alkoxylate having a high degree of alkoxylation of greater than 30 to 150. The first surfactant is present in an amount of from 1% to 50% by weight based on the total weight of the surfactant component. The second surfactant is present in an amount of at least 5% by weight based on the total weight of the surfactant component. Water is present in an amount of from 20% to 90% by weight based on the total weight of the surfactant component. The second surfactant enables higher concentrations of the first surfactant in water to be achieved without gelling than what has been accomplished to date. | 2013-04-18 |
20130096048 | TREATMENT OF SEPSIS AND SEPTIC SHOCK USING GHRELIN AND GROWTH HORMONE - Methods are disclosed for treating sepsis and septic shock using a combination of ghrelin and growth hormone, and for using ghrelin to reduce organ and tissue injury and improve survival after combined radiation exposure and sepsis. | 2013-04-18 |
20130096049 | THERAPEUTIC CONJUGATES - The invention concerns a novel antimicrobial peptide (AMP) polymer conjugate comprising at least one AMP, typically colistin, and a dextrin polymer wherein said dextrin polymer has a molecular weight between 5,000-60,000 g/mol and is modified by the additions of pendant groups which increase the stability of the conjugate and so delays its degradation thereby slowing the rate at which the AMP is released. | 2013-04-18 |
20130096050 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME - This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an a-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived. | 2013-04-18 |
20130096051 | LECTINS AND USES THEREOF - The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and re-search use. In particular, the present invention provides antiviral and antimicrobial lectin compounds (BanLec) isolated from bananas. These compounds have low mitogenicity and pro-inflammatory activity whilst maintaining anti-HIV-1 activity. | 2013-04-18 |
20130096052 | PROCALCITONIN FOR THE DIAGNOSIS OF BACTERIAL INFECTIONS AND GUIDANCE OF ANTIBIOTIC TREATMENT IN PATIENTS WITH NON-SPECIFIC COMPLAINTS - The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints. | 2013-04-18 |
20130096053 | POSACONAZOLE INTRAVENOUS SOLUTION FORMULATIONS STABILIZED BY SUBSTITUTED BETA-CYCLODEXTRIN - The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified β-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties. | 2013-04-18 |
20130096054 | LATENT HUMAN IMMUNODEFICIENCY VIRUS REACTIVIATION - Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-κB activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-κB activity without a second delayed increase in NF-κB activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated | 2013-04-18 |
20130096055 | LONG-ACTING Y2 RECEPTOR AGONISTS - The present invention relates to PYY derivatives comprising a serum albumin binding side chain, wherein said derivative has a half-life of at least 7 hours as determined by Assay (IV) described herein as well as compositions comprising said derivative and its use in therapy. | 2013-04-18 |
20130096056 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS - Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): | 2013-04-18 |
20130096057 | Chemically and Thermodynamically Stable Insulin Analogues and Improved Methods for their Production - The subject matter of this invention is directed towards chemically and thermodynamically stable single-chain insulin (SCI) analogues that are resistant to deamidation and fibrillation. The invention further discloses improved methods for the recombinant expression, purification and refolding of SCI. | 2013-04-18 |
20130096058 | TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS - The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer. | 2013-04-18 |
20130096059 | GLP-1 AGONIST FOR USE IN THE TREATMENT OF STENOSIS OR/AND OBSTRUCTION IN THE BILIARY TRACT - The present invention relates to a pharmaceutical composition for use in the treatment of a disease or condition, wherein said disease or condition is associated (a) stenosis or/and obstruction located in the biliary tract, or/and (b) biliary dyskinesia, said composition comprising at least one GLP-1 agonist and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance. | 2013-04-18 |
20130096060 | GLP-1 AGONIST FOR USE IN THE TREATMENT OF STENOSIS OR/AND OBSTRUCTION IN THE PANCREATIC DUCT SYSTEM - The present invention relates to a pharmaceutical composition for use in the treatment of a disease or condition, wherein said disease or condition is associated with stenosis or/and obstruction located in the pancreatic duct system, said composition comprising at least one GLP-1 agonist and optionally a pharmaceutically acceptable carrier, diluent or/and auxiliary substance. | 2013-04-18 |
20130096061 | METHOD OF TREATING SKELETAL DYSPLASIAS USING VESSEL DILATOR - C-natriuretic peptide (CNP) has been shown to regulate proliferation of mouse and rat osteoblasts. Genetic deletion of CNP results in dwarfism. CNP effects on bone growth involve inhibition of MEK 1 and ERK 1/2 kinases mediated via the intracellular messenger cyclic GMP. Vessel dilator is another natriuretic peptide synthesized by the atrial natriuretic peptide gene whose biologic half-life is 12 times longer than CNP. Vessel dilator's biologic effects on proliferating cells are mediated via inhibiting MEK 1/2 and ERK 1/2 kinases via cyclic GMP. Vessel dilator was not studied previously on osteoblasts. CNP and vessel dilator were tested in dose-response studies enhanced human osteoblasts' proliferation, showing that vessel dilator has identical mechanisms of action to CNP but much longer biologic half-life and effects at lower concentrations. Vessel dilator exhibited therapeutic effect for use in human achondroplasia, short stature and osteoporosis by stimulating osteoblast proliferation. | 2013-04-18 |
20130096062 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 2013-04-18 |
20130096063 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition comprising:
| 2013-04-18 |
20130096064 | FLOWABLE FORMULATIONS FOR TISSUE REPAIR AND REGENERATION - The present invention relates generally to flowable tropocollagen formulations and uses of such formulations for promoting healing and tissue repair and/or regeneration in wounds induced by, for example, trauma or injury, a disease state, bed sores or other pressure ulcers, or surgery. | 2013-04-18 |
20130096065 | NEUBLASTIN VARIANTS - Variant Neublastin polypeptides having substitutions at selected amino acid residues are disclosed. Substitution at one or more selected amino acid residues decreases heparin binding and increases serum exposure of variant Neublastin polypeptides. Also disclosed are methods of using variant Neublastin polypeptides to treat disorders and activate the RET receptor in a mammal. | 2013-04-18 |
20130096066 | PHARMACEUTICAL FORMULATION FOR REDUCING PAIN - The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil. | 2013-04-18 |
20130096067 | DROSOPHILA TUMOR STEM CELL MODEL AND USES THEREOF - The present invention provides a transgenic | 2013-04-18 |
20130096068 | COMBINATION THERAPY WITH A PROTEASOME INHIBITOR AND A GALLIUM COMPLEX - A combination therapy is disclosed for treating cancer. The method comprises identifying a patient diagnosed of cancer and in need of treatment, administering to a cancer patient a therapeutically effective amount of a compound of Formula (I), and administering to said patient a therapeutically effective amount of a proteasome inhibitor. | 2013-04-18 |
20130096069 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES - This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length. | 2013-04-18 |
20130096070 | PEPTIDE TARGETING OF INNER EAR CELLS - Peptide targeting moieties that target the cells of the inner ear can be used for targeted therapeutics. As such, nucleic acids and/or drugs can be associated with the targeting moieties in order to provide therapeutics that are delivered to specific cells in the inner ear. Conjugation of drugs or gene therapy vectors to cell specific peptides may allow the treatment of individual cell types within the inner ear. The peptide targeting moieties can be polypeptides having the sequences of Table 1 in an unnatural configuration. The polynucleotide can either consist of the sequence or include additional polypeptides attached to the ends of the sequences shown in Table 1. The polynucleotide can be in a non-native configuration. For example, the polypeptide is selected from the following: a-h-p-h-h-s-m (SEQ ID NO: 12); h-p-h-h-r-i-f (SEQ ID NO: 29); t-v-p-q-l-t-t (SEQ ID NO: 1); s-t-t-k-l-a-l (SEQ ID NO: 2); m-e-g-y-i-h-r (SEQ ID NO: 3); h-a-i-y-p-r-h (SEQ ID NO: 5); h-s-r-l-l-d-q (SEQ ID NO: 6); i-q-s-p-h-f-f (SEQ ID NO: 7); or y-a-a-h-r-s-h (SEQ ID NO: 8). | 2013-04-18 |
20130096071 | Agonists of Guanylate Cyclase Useful For the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders - The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer. | 2013-04-18 |
20130096072 | Zymogen Activators - Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides. | 2013-04-18 |
20130096073 | Casein Derived Peptides And Uses Thereof - Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the αS1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases, alone or in combination with other peptides or blood cell stimulating factors. | 2013-04-18 |
20130096074 | PROTEIN HYDROLYSATE ENRICHED IN PEPTIDES INHIBITING DPP-IV AND THEIR USE - Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder. | 2013-04-18 |
20130096075 | COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF METABOLIC SYNDROME - A composition comprising (a) and (b), and a food or drink or a medicine comprising the composition, wherein
| 2013-04-18 |
20130096076 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR - The invention relates to a pharmaceutical composition according to claim | 2013-04-18 |
20130096077 | Nematicidal Mixtures for Use in Sugar Cane - A method for the synergistic plant nematode control in sugar cane with a mixture of fipronil and abamectin comprising fipronil and abamectin in a ratio by weight of from 1:10 to 10:1, wherein the mixture is applied to sugar cane in furrow, a method for the synergistic plant nematode control in sugar cane with a mixture of fipronil and abamectin comprising fipronil and abamectin in a ratio by weight of from 1:10 to 10:1, wherein the mixture is applied to plant propagation materials of sugar cane, and a method which combines synergistic plant nematode control with (preferably synergistic) improvement of the plant health of sugar cane plants. | 2013-04-18 |
20130096078 | NEW KANAMYCIN COMPOUND, KANAMYCIN-PRODUCING STREPTOMYCES SPECIES BACTERIUM, AND METHOD OF PRODUCING KANAMYCIN - Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, | 2013-04-18 |
20130096079 | Anti-Viral Pyrimidine Nucleoside Derivatives - A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH | 2013-04-18 |
20130096080 | STERILE ALGINATE-BASED AQUEOUS COMPOSITION FOR MEDICAL USE AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to ready-to-use sterile, alginate-based, aqueous compositions for medical use. More particularly, the invention relates to an aqueous composition for medical use that has been sterilized by heat sterilization and having a viscosity at 25° C. of at least 300 cP) (Helipath® T F spindle, 100 rpm at 25° C.), said composition having a pH in the range of 6.5-7.5; containing 0.5-10 wt. % of an alginate salt; and further containing 10-500 mM of one or more dissolved C | 2013-04-18 |
20130096081 | DERMAL FILLER COMPOSITIONS - The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions made with a di-amine or multiamine crosslinker in the presence of a carbodiimide coupling agent. | 2013-04-18 |
20130096082 | HEMOSTATIC COMPOSITIONS - The invention discloses a hemostatic composition composing chitin or a water insoluble chitin derivative, especially water insoluble chitosan, in particulate form, wherein the composition is present in paste form. | 2013-04-18 |
20130096083 | USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME - The use of isoquinolones for preparing drugs, including novel isoquinolones as well as their synthesis method. In particular, isoquinolone derivatives used in the treatment of pathological angiogenesis, and more particularly of cancer. | 2013-04-18 |
20130096084 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS - The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. | 2013-04-18 |
20130096085 | PROCHELATORS USEFUL FOR INHIBITING METAL-ASSOCIATED TOXICITY - Prochelator compounds of Formula (I) or Formula (II) are described, along with methods of using the same and pharmaceutical formulations or compositions containing the same. | 2013-04-18 |
20130096086 | MITOCHONDRIA AND HUMAN IMMUNODEFIENCY VIRUS TYPE 1 - Methods described herein relate to mitochondria and their role in Human immunodeficiency virus type 1 (HIV-1) infection and cell-to-cell HIV-1 transmission and compositions and methods for modulating mitochondrial mediated cell-to-cell transmission of HIV-1. Methods for screening to identify inhibitors of mitochondrial mediated cell-to-cell transmission of HIV-1 are also envisioned herein. | 2013-04-18 |
20130096087 | INFANT NUTRITION FOR IMPROVING FATTY ACID COMPOSITION OF BRAIN MEMBRANES - The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes. | 2013-04-18 |
20130096088 | Inhibitors of Protein Tyrosine Kinase Activity - The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling. | 2013-04-18 |
20130096089 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders - Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed. | 2013-04-18 |
20130096090 | TRANSITION METAL COMPLEXES OF AMINO ACIDS AND RELATED LIGANDS AND THEIR USE AS CATALYSTS, ANTI-MICROBIALS, AND ANTI-CANCER AGENTS - The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the present invention provide transition metal complexes of amino acids. Transition metal complexes of embodiments of the invention according to Categories I, II, III, and/or IV may be used as antimicrobial, anti-malarial, and anti-cancer agents, as well as catalysts in chemical reactions. Such compounds of the invention are particularly useful for combating multi-drug resistance against a broad range of microbials (such as MRSA and mycobacteria), including gram positive and gram negative bacteria, as well as can be used as anti-cancer agents against bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, and thyroid cancer, to name a few. | 2013-04-18 |
20130096091 | COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS, AND MANUFACTURING METHOD THEREFOR - The present invention relates to a composition for preventing or treating osteoporosis which comprises an ibandronic acid, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and vitamin D. The present invention relates to a composition for preventing or treating osteoporosis which has uniform medicinal effects by minimizing the differences in physical properties between ibandronic acid, or the pharmaceutically acceptable salt thereof, or the hydrate thereof, and vitamin D. | 2013-04-18 |
20130096092 | THIOETHER PRODRUG COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS - Disclosed are inhibitors of retroviral growth of formula (I), that are useful in treatment of retroviral infections such as HIV. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, a method for inactivating a virus, a method for dissociating a metal ion from a zinc finger-containing protein, and a method for inhibiting the transmission of a virus. | 2013-04-18 |
20130096093 | COMPOSITIONS AND METHODS OF TREATMENT FOR INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 2013-04-18 |
20130096094 | Derivatives of 3-O-(3',3'-dimethylsuccinyl)-betulinic acid - The present invention relates to compounds of the following formula (I): | 2013-04-18 |
20130096095 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR - The present invention provides tetrahydropyrvinium (THP), derivatives thereof, benzoxazole compounds, and derivatives thereof. The present invention provides a method of using tetrahydropyrvinium (THP), derivatives thereof, benzoxazole compounds, and derivatives thereof. | 2013-04-18 |
20130096096 | VISCOUS BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 2013-04-18 |
20130096097 | PHARMACEUTICAL MULTIMERIC PARTICLES, AND MANUFACTURING METHOD FOR SAME - [Problem] The purpose of the present invention is to provide organic particles containing pharmaceutical particles of which the particles are small and the particle size distribution is narrow, and a manufacturing method for the same. | 2013-04-18 |
20130096098 | Light Insensitive Silver(i) Cyanoximates As Antimicrobial Agents For Indwelling Medical Devices - Silver(I) cyanoximates of AgL composition (L=NC—C(NO)—R, where R is electron withdrawing groups: —CN, —C(O)NR | 2013-04-18 |
20130096099 | METHOD OF TREATING BRAIN CANCER - A therapeutic method for treating brain cancer is disclosed comprising administering to a patient in need of treatment a ruthenium complex salt. | 2013-04-18 |
20130096100 | DI(ARYLAMINO)ARYL COMPOUND - The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. | 2013-04-18 |
20130096101 | INHIBITORS OF HCV NS5A - Provided herein are compounds, pharmaceutical compositions, and combination therapies for inhibition of hepatitis C. | 2013-04-18 |
20130096102 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS - Compounds of the formula I: | 2013-04-18 |
20130096103 | IMIDAZOQUINOLINE COMPOUNDS - The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s). | 2013-04-18 |
20130096104 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention provides compounds of Formulas Ia-Ib, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R | 2013-04-18 |
20130096105 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors - The present invention provides a compound of formula (I): | 2013-04-18 |
20130096106 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - Compounds represented by formula: | 2013-04-18 |
20130096107 | USE OF AMINODIHYDROTHIAZINES FOR THE TREATMENT OR PREVENTION OF DIABETES - This invention relates to compounds of formula I, | 2013-04-18 |
20130096108 | Cyclic Inhibitors of 11Beta-Hydroxysteroid Dehydrogenase 1 - Disclosed is a compound represented by Formula (Im | 2013-04-18 |
20130096109 | PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY - An object of the present invention is to provide a novel integrase inhibitor. The present invention relates to a novel compound having an antiviral effect, more specifically, a pyridone derivative having HIV integrase inhibitory activity, and a medicament containing the same, in particular, an anti-HIV agent. The compound of the present invention has integrase inhibitory activity and/or cell proliferation inhibitory activity against viruses, in particular, HIV and drug-resistant strains thereof. Thus, the compound is useful in preventing or treating various diseases, viral infections (for example, AIDS), and the like in which integrase participates. | 2013-04-18 |
20130096110 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction - Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction. | 2013-04-18 |
20130096111 | Methods Involving Aldose Reductase Inhibitors - Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of inflammation, including uveitis and asthma. | 2013-04-18 |
20130096112 | FURO[3,2-G]CHROMENE COMPOUNDS AND USES THEREOF - Disclosed are furo[3,2-g]chromene derivatives represented by formula (I), stereoisomers, pharmaceutically acceptable salts, and pharmaceutical compositions thereof, as well as uses thereof as estrogen receptor modulators. | 2013-04-18 |
20130096113 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF - Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 2013-04-18 |
20130096114 | PHARMACOKINETICALLY IMPROVED COMPOUNDS - A compound of formula A having improved non-specific binding characteristics and pharmacokinetic properties is provided: | 2013-04-18 |
20130096115 | METHODS FOR TREATING AUTISM - Provided herein are PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from autism. | 2013-04-18 |
20130096116 | TREATMENT OF PHARMACOLOGICAL-INDUCED HYPOCHLORHYDRIA - Changes in gastric pH due to oral co-administration of acid-reducing agents, such as proton pump inhibitors, and oncology drugs can have a marked impact on the absorption and oral bioavailability of the oncology drug if the pH decreases the maximal absorbable dose. Moreover, there is a potential for specific drug-drug interactions between some of the acid-reducing agents and these drugs. Methods are described for treating patients on gastric acid-reducing therapy with orally-administered PI3K inhibitor compound GDC-0941. Treatment with a re-acidification compound during treatment with GDC-0941 improves bioavailability of GDC-0941. | 2013-04-18 |
20130096117 | Novel Compounds - The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): | 2013-04-18 |
20130096118 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS - Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, formula (I) are useful as kinase modulators, including Btk modulation. | 2013-04-18 |
20130096119 | Isoquinolin-3-Ylurea Derivatives - The invention relates to isoquinolin-3-ylurea derivatives of formula (I) wherein R | 2013-04-18 |
20130096120 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein. | 2013-04-18 |
20130096121 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bc1-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bc1-xL protein. | 2013-04-18 |
20130096122 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS - The present invention relates to sodium channel inhibitors of Formula I: | 2013-04-18 |
20130096123 | RADIATION SENSITISER COMPOSITIONS - The invention provides an oral liquid composition of a hypoxic radiation sensitiser comprising the radiation sensitiser in a concentration of greater than 5 mg/ml, and a method of treating a subject with a hypoxic condition comprising administration to the subject of a combination of a composition of the invention and radiation. | 2013-04-18 |
20130096124 | 5-ARYL ISOXAZOLINES FOR CONTROLLING PESTS - The present invention relates to new isoxazoline compounds of formula | 2013-04-18 |
20130096125 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PAHRMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS - Disclosed are novel rhodanine derivatives which are inhibitory of HIV activity. Also provided are a method for preparing the novel rhodanine derivatives, and a pharmaceutical composition for the prevention or treatment of AIDS containing the rhodanine derivatives as active ingredients. Having high inhibitory activity against HIV, the rhodanine derivatives can be effectively used in the prophylaxis or therapy of AIDS. | 2013-04-18 |
20130096126 | METHOD FOR ENHANCING LEARNING AND MEMORY IMPAIRED BY NEURODEGENERATIVE DISORDERS AND COMPOUNDS AND COMPOSITIONS FOR EFFECTING THE SAME - A method for enhancing learning or memory of both in a mammal having impaired learning or emory of both from a neuro-degenerative disorder, which entails the step of administering at least one compound or a salt thereof which is a β | 2013-04-18 |
20130096127 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS - The present invention provides a compound of formula I′; | 2013-04-18 |
20130096128 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS - This invention describes novel pyrazole compounds of formula III: | 2013-04-18 |
20130096129 | ACTIVATORS OF CLASS I HISTONE DEACETLYASES (HDACS) AND USES THEREOF - The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D). | 2013-04-18 |
20130096130 | CGRP Receptor Antagonists - The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). | 2013-04-18 |
20130096131 | OPTICAL CORRECTION - The present disclosure describes compositions which improve visual acuity and to methods for their use. | 2013-04-18 |
20130096132 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE - The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes. | 2013-04-18 |
20130096133 | PROCASPASE-ACTIVATING COMPOUNDS AND COMPOSITIONS - The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells. | 2013-04-18 |
20130096134 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2013-04-18 |
20130096135 | Selected Inhibitors of Protein Tyrosine Kinase Activity - The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling. | 2013-04-18 |
20130096136 | Inhibitors of Protein Tyrosine Kinase Activity - The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling. | 2013-04-18 |
20130096138 | NOVEL THIOUREA OR UREA DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING SAME AS ACTIVE INGREDIENT - Disclosed are novel thiourea or urea derivatives inhibitory of HIV activity. Also provided are a method for preparing the thiourea or urea derivatives, and a pharmaceutical composition for the prophylaxis or therapy of AIDS comprising the derivatives. Having high inhibitory activity against HIV, the thiourea or urea derivatives can be effectively used in the prophylaxis or therapy of AIDS. | 2013-04-18 |
20130096139 | Compounds Useful as Inhibitors of ATR Kinase - The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. | 2013-04-18 |
20130096140 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE - The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis. | 2013-04-18 |
20130096141 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF - Compounds of structural formula I: are GPR119 agonists and are useful for the treatment, control or prevention of disorders responsive to agonism of GPR119, such as metabolic-related disorders such as type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia or syndrome X. The compounds are also reported as being useful for controlling weight gain, controlling food intake, and inducing satiety in mammals. | 2013-04-18 |
20130096142 | METHODS FOR HEALTHY AGING - Genome-wide association studies have been used to elucidate genes and/or pathways related to diseases; however, this methodology has yet to be used to understand the phenotype of healthy aging and/or healthspan in humans. | 2013-04-18 |
20130096143 | N-ACYL AMINO ACID DERIVATIVES FOR TREATING SKIN CONDITIONS SUCH AS CELLULITE - The invention relates to small molecules having biological and therapeutic activity. Particularly, the invention relates to small molecules having lipolytic and anti-adipogenic activity. Two examples of such molecules are 4-methyl-2-(octanoylamino) pentanoic acid and N-isopentyloctanamide. The invention further relates to methods of preventing or treating skin conditions such as cellulite using small molecules having lipolytic and anti-adipogenic activity. | 2013-04-18 |
20130096144 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS - The present invention provides isoindolinone and pyrrolopyridinone derivatives, as well as their compositions and methods of use, that inhibit the activity of the serine/threonine kinase, Akt, and are useful in the treatment of diseases related to the activity of Akt including, for example, cancer and other diseases. | 2013-04-18 |
20130096145 | Use of 1H-quinazoline-2,4-diones - The invention concerns the use of competitive AMPA receptor antagonists for the treatment, prevention or delay of progression of spasticity. | 2013-04-18 |
20130096146 | Tricyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof - The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells. | 2013-04-18 |